AYTU BIOPHARMA, INC Long-term Debt and Lease Obligation, Including Current Maturities
AYTU BIOPHARMA, INC (AYTU) had Long-term Debt and Lease Obligation, Including Current Maturities of $10.96 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Balance Sheet › Liabilities › Debt
us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities · last filed 2026-09-22
- 2026-06-30: Long-term Debt and Lease Obligation, Including Current Maturities $10.96M.
- 2026-03-31: Long-term Debt and Lease Obligation, Including Current Maturities $11.41M.
- 2025-12-31: Long-term Debt and Lease Obligation, Including Current Maturities $11.86M.
- 2025-09-30: Long-term Debt and Lease Obligation, Including Current Maturities $12.30M.
| Period end | Long-term Debt and Lease Obligation, Including Current Maturities |
|---|---|
| 2026-06-30 | $10.96M 10-K · filed 2026-09-22 |
| 2026-03-31 | $11.41M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $11.86M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $12.30M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $12.75M 10-K · filed 2026-09-22 |
| 2025-03-31 | $11.39M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $11.84M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $12.29M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $12.73M 10-K · filed 2025-09-23 |
| 2024-03-31 | $15.13M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $15.02M 10-Q · filed 2024-02-14 |
| 2023-09-30 | $14.90M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $14.80M 10-K · filed 2024-09-26 |
| 2023-03-31 | $14.69M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $14.62M 10-Q · filed 2023-02-21 |
| 2022-09-30 | $14.48M 10-Q/A · filed 2023-02-21 |
| 2022-06-30 | $14.38M 10-Q · filed 2023-05-11 |
| 2022-03-31 | $14.27M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |